125 related articles for article (PubMed ID: 3770034)
1. Pharmacokinetics and efficacy of i.v. and i.p. VM26 chemotherapy in mice bearing Krebs II ascitic tumors.
Canal P; Bugat R; Rokoszak B; Berg D; Soula G; Roche H
Eur J Cancer Clin Oncol; 1986 Jul; 22(7):765-71. PubMed ID: 3770034
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of teniposide in patients with ovarian cancer.
D'Incalci M; Rossi C; Sessa C; Urso R; Zucchetti M; Farina P; Mangioni C
Cancer Treat Rep; 1985 Jan; 69(1):73-7. PubMed ID: 3967261
[TBL] [Abstract][Full Text] [Related]
3. Uptake and binding of teniposide (VM26) in Krebs II ascites cells.
Hamza M; Canal P; Bugat R; Soula G; Douste-Blazy L
Biochem Pharmacol; 1987 May; 36(10):1599-603. PubMed ID: 3109424
[TBL] [Abstract][Full Text] [Related]
4. Activity and pharmacokinetics of teniposide in Lewis lung carcinoma-bearing mice.
Broggini M; Colombo T; D'Incalci M
Cancer Treat Rep; 1983 Jun; 67(6):555-9. PubMed ID: 6861161
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy of the epipodophyllotoxin derivatives, teniposide and etoposide. A pharmacodynamic rationale?
Allen LM; Tejada F; Okonmah AD; Nordqvist S
Cancer Chemother Pharmacol; 1982; 7(2-3):151-6. PubMed ID: 7083456
[TBL] [Abstract][Full Text] [Related]
6. Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy.
Giaccone G; Donadio M; Bonardi G; Testore F; Calciati A
J Clin Oncol; 1988 Aug; 6(8):1264-70. PubMed ID: 2842464
[TBL] [Abstract][Full Text] [Related]
7. A case of small cell lung cancer successfully treated with VM26.
Suga J; Saijo N; Shinkai T; Eguchi K; Sasaki Y; Sakurai M; Sano T; Tamura T; Morinaga S
Jpn J Clin Oncol; 1986 Jun; 16(2):123-8. PubMed ID: 3016377
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic study of VM26 given as a prolonged IV infusion to ovarian cancer patients.
Rossi C; Zucchetti M; Sessa C; Urso R; Mangioni C; D'Incalci M
Cancer Chemother Pharmacol; 1984; 13(3):211-4. PubMed ID: 6488441
[TBL] [Abstract][Full Text] [Related]
9. Teniposide (VM26) as second-line treatment for small cell lung cancer.
Tummarello D; Guidi F; Torresi U; Dazzi C; Cellerino R
Anticancer Res; 1990; 10(2A):397-9. PubMed ID: 2161198
[TBL] [Abstract][Full Text] [Related]
10. Teniposide (VM26) disposition in children with leukemia.
Sinkule JA; Stewart CF; Crom WR; Melton ET; Dahl GV; Evans WE
Cancer Res; 1984 Mar; 44(3):1235-7. PubMed ID: 6581866
[TBL] [Abstract][Full Text] [Related]
11. Effect of cyclosporin A on protein binding of teniposide in cancer patients.
Toffoli G; Aita P; Sorio R; Corona G; Bertola A; Colussi AM; Robieux I; Boiocchi M
Anticancer Drugs; 1999 Jul; 10(6):511-8. PubMed ID: 10885897
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of teniposide (VM26) in cutaneous T-cell lymphomas.
Sorio R; Tirelli U; Zagonel V; Carbone A; Monfardini S
Am J Clin Oncol; 1990 Feb; 13(1):14-6. PubMed ID: 2305716
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposide.
Toffoli G; Sorio R; Gigante M; Corona G; Galligioni E; Boiocchi M
Br J Cancer; 1997; 75(5):715-21. PubMed ID: 9043030
[TBL] [Abstract][Full Text] [Related]
14. In vitro antitumor activity of teniposide against carcinoma of the lung in human tumor clonogenic assay.
Matsushima Y; Kanzawa F; Miyazawa N; Sasaki Y; Saijo N
Anticancer Res; 1986; 6(5):921-4. PubMed ID: 3026235
[TBL] [Abstract][Full Text] [Related]
15. Teniposide (VM26): an effective treatment for brain metastases of small cell carcinoma of the lung.
Giaccone G; Donadio M; Bonardi GM; Testore F; Calciati A
Eur J Cancer Clin Oncol; 1988 Apr; 24(4):629-31. PubMed ID: 2838291
[TBL] [Abstract][Full Text] [Related]
16. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide.
Long BH; Musial ST; Brattain MG
Cancer Res; 1986 Aug; 46(8):3809-16. PubMed ID: 3015377
[TBL] [Abstract][Full Text] [Related]
17. [Phase I trial and pharmacokinetics of VM 26 combined with cisplatin administered by the intraperitoneal route without mixing time].
Chatelut E; Canal P; De Forni M; Chevreau C; Houin G; Bugat R
Bull Cancer; 1989; 76(8):893-6. PubMed ID: 2620120
[No Abstract] [Full Text] [Related]
18. Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer.
Evans WE; Sinkule JA; Crom WR; Dow L; Look AT; Rivera G
Cancer Chemother Pharmacol; 1982; 7(2-3):147-50. PubMed ID: 7083455
[TBL] [Abstract][Full Text] [Related]
19. A phase II study with teniposide (VM26) in patients with progressed or relapsed small cell lung cancer (SCLC).
Tummarello D; Guidi F; Di Furia L; Gramazio A; Menichetti E; Cellerino R
J Chemother; 1989 Feb; 1(1):64-7. PubMed ID: 2542470
[TBL] [Abstract][Full Text] [Related]
20. [The toxicity of massive dosis of VM26 (4-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside). A contribution to the therapy of advanced ovarian cancer (author's transl)].
Jankowski RP; Vahrson H
Med Klin; 1977 Dec; 72(49):2122-6. PubMed ID: 337083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
